Nkarta (NKTX) Non-Current Deffered Revenue (2019 - 2020)
Nkarta's quarterly Non-Current Deffered Revenue came in at $3.6 million in Q2 2020, up 3355.96% quarter-over-quarter from $104030.0 in Q4 2019.
Nkarta has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $3.6 million in Q2 2020.
- For the quarter ending Q2 2020, Non-Current Deffered Revenue changed N/A year-over-year to $3.6 million; the trailing twelve-month figure through Jun 2020 stood at $3.6 million (changed N/A YoY), and the FY2019 full-year result was $104030.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q2 2020 stood at $3.6 million, up from $104030.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $3.6 million in Q2 2020, with the low at $104030.0 in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 3.60 Mn |
| Dec 31, 2019 | 104,030.00 |